Burkholderia in CF
Burkholderia cepacia complex (Bcc) infection in cystic fibrosis is among the most feared complications in the field: these intrinsically multidrug-resistant Gram-negative bacteria can cause “cepacia syndrome,” a rapidly fatal necrotizing pneumonia, and chronic Bcc infection is a contraindication to lung transplantation at many centers. With few or no reliable antibiotics, lytic bacteriophages are an attractive precision option because they kill by a mechanism orthogonal to antibiotic resistance and can be matched to a patient’s specific Burkholderia strain.
How phages act here
Mechanism
Therapeutic Burkholderia phages are strictly lytic viruses selected against the patient’s isolate; many recognize the bacterial lipopolysaccharide or surface polysaccharides and some encode depolymerases that strip the protective exopolysaccharide, potentially re-sensitizing the organism to host immunity and antibiotics. Because Bcc host ranges are narrow and the genus is genetically diverse, cocktails of several phages plus phage–antibiotic combinations are used to broaden coverage and suppress resistance. A practical challenge is the relative scarcity of well-characterized, strictly lytic Burkholderia phages compared with Pseudomonas or Staphylococcus, which makes biobanking and rapid host-range matching especially important here.
Where it stands
Current evidence
Evidence is preclinical and early compassionate-use. Multiple groups have isolated and characterized lytic Bcc phages and shown efficacy in vitro and in infection models (e.g., Galleria and murine lung models), and individual CF patients with Bcc have received personalized phage therapy on a compassionate-use basis. No controlled clinical trial of phage therapy for Burkholderia in CF has yet reported, so this remains an investigational, case-by-case indication.
Evidence confidence: low
The data
Key studies & trials
Who is working on it
Programs & centers
The possibility
A well-curated Burkholderia phage bank paired with rapid strain matching could give the most desperate CF patients — those with cepacia syndrome or transplant-disqualifying chronic infection — a precision option where antibiotics offer almost none, potentially turning a transplant contraindication into a manageable infection.